UTAH MEDICAL PRODUCTS INC - Common Shares (UTMD)

Historical Holders from Q1 2014 to Q3 2025

Symbol
UTMD on Nasdaq
Type / Class
Equity / Common Shares
Shares outstanding
3,203,885
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
2,162,566
Holdings value
$136,207,719
% of all portfolios
0%
Number of holders
114
Number of buys
50
Number of sells
-40
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of UTAH MEDICAL PRODUCTS INC - Common Shares (UTMD)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BRANDES INVESTMENT PARTNERS, LP 10.4% +25% $18,559,463 +$3,434,852 333,204 +22.7% BRANDES INVESTMENT PARTNERS, LP 31 Aug 2025
RENAISSANCE TECHNOLOGIES LLC 6.7% $12,107,235 230,614 Renaissance Technologies LLC 30 Sep 2024
DIMENSIONAL FUND ADVISORS LP 6.1% $11,239,863 197,466 Dimensional Fund Advisors LP 30 Jun 2025
BlackRock, Inc. 5.3% +6.6% $9,829,260 +$231,666 172,684 +2.4% BlackRock, Inc. 30 Jun 2025
FMR LLC 2.7% $4,848,900 92,360 FMR LLC 31 Dec 2024

Institutional Holders of UTAH MEDICAL PRODUCTS INC - Common Shares (UTMD)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 2,162,566 $136,207,719 +$705,415 $62.97 114
2025 Q2 2,154,610 $122,645,130 -$4,286,491 $56.92 109
2025 Q1 2,232,321 $125,139,291 -$4,053,654 $56.04 107
2024 Q4 2,305,146 $141,733,881 -$6,984,040 $61.47 112
2024 Q3 2,408,468 $161,160,273 +$1,503,694 $66.91 109
2024 Q2 2,402,050 $160,517,663 -$6,987,298 $66.81 99
2024 Q1 2,489,842 $177,079,892 -$5,994,623 $71.11 99
2023 Q4 2,515,087 $211,858,896 -$5,241,769 $84.22 88
2023 Q3 2,572,783 $221,288,021 +$1,886,299 $86 91
2023 Q2 2,546,722 $237,462,990 +$487,123 $93.2 89
2023 Q1 2,542,875 $241,013,763 +$8,482,645 $94.77 86
2022 Q4 2,546,245 $255,980,665 +$1,190,438 $100.53 81
2022 Q3 2,535,532 $216,324,656 -$31,278,340 $85.31 75
2022 Q2 2,559,522 $219,885,103 -$450,030 $85.9 74
2022 Q1 2,572,731 $231,180,696 -$2,805,351 $89.86 84
2021 Q4 2,603,370 $260,419,500 -$912,880 $100 78
2021 Q3 2,601,860 $241,516,691 +$243,574 $92.83 72
2021 Q2 2,599,575 $221,087,106 -$2,811,784 $85.04 68
2021 Q1 2,632,036 $227,952,680 +$1,009,922 $86.6 78
2020 Q4 2,620,725 $220,943,842 -$2,326,872 $84.3 76
2020 Q3 2,651,007 $211,813,071 -$2,768,168 $79.87 83
2020 Q2 2,681,470 $237,657,730 +$3,950,332 $88.62 91
2020 Q1 2,628,004 $247,165,094 -$14,110,945 $94.05 89
2019 Q4 2,771,884 $299,105,893 -$7,842,685 $107.9 95
2019 Q3 2,845,261 $272,705,817 +$14,362,424 $95.84 94
2019 Q2 2,695,866 $257,857,946 +$3,901,787 $95.7 96
2019 Q1 2,667,666 $235,422,594 -$153,905 $88.25 90
2018 Q4 2,678,889 $222,557,936 -$9,708,244 $83.08 85
2018 Q3 2,788,384 $262,649,786 +$18,705,556 $94.2 89
2018 Q2 2,586,431 $284,806,927 +$1,054,670 $110.15 91
2018 Q1 2,585,740 $255,600,294 +$9,117,799 $98.85 78
2017 Q4 2,497,435 $203,092,527 +$2,126,789 $81.4 78
2017 Q3 2,480,589 $182,487,296 +$233,743 $73.55 74
2017 Q2 2,477,645 $179,356,830 +$4,870,819 $72.4 75
2017 Q1 2,421,128 $150,830,508 +$6,332,169 $62.3 76
2016 Q4 2,477,886 $180,211,111 -$462,985 $72.75 75
2016 Q3 2,500,148 $149,501,799 -$1,271,482 $59.8 78
2016 Q2 2,519,897 $158,750,245 -$2,050,779 $63 76
2016 Q1 2,555,094 $159,803,564 +$3,079,935 $62.54 68
2015 Q4 2,531,311 $148,131,615 +$2,531,634 $58.54 65
2015 Q3 2,466,259 $133,025,937 -$477,134 $53.87 58
2015 Q2 2,473,912 $147,468,790 +$3,581,938 $59.63 63
2015 Q1 2,413,527 $144,447,777 -$3,605,115 $59.86 59
2014 Q4 2,473,676 $148,510,172 -$16,219 $60.05 60
2014 Q3 2,205,551 $107,547,653 -$11,678,366 $48.76 60
2014 Q2 2,427,382 $124,860,931 +$1,473,685 $51.44 60
2014 Q1 2,397,038 $138,529,175 +$3,536,633 $57.83 58